K
Kwang Hyub Han
Researcher at Yonsei University
Publications - 694
Citations - 36674
Kwang Hyub Han is an academic researcher from Yonsei University. The author has contributed to research in topics: Hepatocellular carcinoma & Hepatitis B virus. The author has an hindex of 80, co-authored 692 publications receiving 30974 citations. Previous affiliations of Kwang Hyub Han include University Health System.
Papers
More filters
Journal ArticleDOI
Hepatitis C Virus and Antiviral Drug Resistance.
TL;DR: Despite the clinical challenges in the management of chronic hepatitis C, substantial progress has been made in understanding HCV, which may facilitate the investigation of other closely related flaviviruses and lead to the development of antiviral agents against these human pathogens.
Journal ArticleDOI
Predictive value of liver cell dysplasia for development of hepatocellular carcinoma in patients with chronic hepatitis B.
Ja Seung Koo,Haeryoung Kim,Byung Kyu Park,Sang Hoon Ahn,Kwang Hyub Han,Chae Yoon Chon,Chanil Park,Young Nyun Park +7 more
TL;DR: In this paper, the presence of large liver cell dysplasia (LLCD) and/or small LCD (SLCD) in chronic hepatitis B is a risk factor for hepatocellular carcinoma (HCC) development.
Transient elastography in chronic hepatitis B: an Asian perspective
TL;DR: It is found that the diagnostic performance and cutoff values were different between the 2 populations possibly as a result of several different confounders between Asian and European populations.
Journal ArticleDOI
Results of up to 2 years of entecavir vs lamivudine therapy in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B.
Ting-Tsung Chang,You-Chen Chao,V. V. Gorbakov,Kwang Hyub Han,Robert G. Gish,R. De Man,Hugo Cheinquer,Fernando Bessone,Helena Brett-Smith,Ricardo Tamez +9 more
TL;DR: For responders who discontinued therapy (per protocol), 24‐week off‐treatment evaluation is presented to provide a more ‘complete picture’ of what clinicians can expect when treating nucleoside‐naïve HBeAg‐positive patients with chronic hepatitis B.
Journal ArticleDOI
A survey on transarterial chemoembolization refractoriness and a real-world treatment pattern for hepatocellular carcinoma in Korea
Jae Seung Lee,Beom Kyung Kim,Seung Up Kim,Jun Yong Park,Sang Hoon Ahn,Jinsil Seong,Kwang Hyub Han,Do Young Kim +7 more
TL;DR: Overall, sorafenib therapy and radiotherapy were preferred when repeated TACE was considered ineffective, and experts need to continue discussions on the standardization and sub-classification of HCC treatment guidelines in Korea.